Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Accessibility StatementSkip Navigation Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention SEATTLE, Nov. 6, 2025 /PRNewswire/ --Â Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on Decembe ...